AMO Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AMO Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11024
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AMO Pharma Ltd (Amo Pharma) is a biopharmaceutical company that develops novel treatments for serious and debilitating diseases. The company provides pipeline product portfolio such as AMO-01, and AMO-02. Its AMO-01 is being developed for the treatment of autism and intellectual disabilities. It is an inhibitor of the ras-extracellular signal-regulated kinase pathway (Ras-ERK). AMO Pharma offers AMO-02 which is used for the treatment of myotonic dystrophy, CNS, neuromuscular and oncology indications, among others. It is an inhibitor of glycogen synthase kinase 3 beta. The company provides target therapy areas such as central nervous system disorders, neuromuscular and Steinert’s disease. It also has operations in the US and the UK. Amo Pharma is headquartered in London, the UK.

AMO Pharma Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
AMO Pharma Enters into Agreement with Ranedis Pharma 10
Licensing Agreements 11
AMO Pharma Enters into Licensing Agreement with Numedicus 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
Equity Offering 13
AMO Pharma Raises USD25 Million in Financing 13
AMO Pharma Ltd – Key Competitors 14
AMO Pharma Ltd – Key Employees 15
AMO Pharma Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AMO Pharma Enters into Agreement with Ranedis Pharma 10
AMO Pharma Enters into Licensing Agreement with Numedicus 11
Bellus Health Enters into Licensing Agreement with AMO Pharma 12
AMO Pharma Raises USD25 Million in Financing 13
AMO Pharma Ltd, Key Competitors 14
AMO Pharma Ltd, Key Employees 15
AMO Pharma Ltd, Other Locations 16

List of Figures
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AMO Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[AMO Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Deyaar Development:企業の戦略・SWOT・財務情報
    Deyaar Development - Strategy, SWOT and Corporate Finance Report Summary Deyaar Development - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Novartis Pharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Novartis Pharmaceuticals Corp (Novartis), a subsidiary of Novartis AG is a developer, manufacturer and distributor of active ingredients, patent protected medicines and treatments for the healthcare industry. The company’s products include innovative prescription medicine and drugs, tablets, …
  • Stanmore Coal Ltd:企業の戦略・SWOT・財務情報
    Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report Summary Stanmore Coal Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Impellam Group plc (IPEL):企業の財務・戦略的SWOT分析
    Impellam Group plc (IPEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Zara Investment (Holding) Co Ltd:企業の戦略・SWOT・財務分析
    Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zara Investment (Holding) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • The Boston Beer Co Inc (SAM):企業の財務・戦略的SWOT分析
    The Boston Beer Co Inc (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • AIA Group Limited:戦略・SWOT・企業財務分析
    AIA Group Limited - Strategy, SWOT and Corporate Finance Report Summary AIA Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Industrija nafte d.d. (INA-R-A):石油・ガス:M&Aディール及び事業提携情報
    Summary Industrija nafte dd (INA) is an integrated energy company, which operates across the energy value chain from exploration and production to refining and marketing to retail. It has interests in offshore and onshore assets in Croatia, Egypt, and Angola. The company manages refineries in Rijeka …
  • American Builders & Contractors Supply Co Inc:企業の戦略・SWOT・財務情報
    American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report Summary American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • McKinsey & Co Inc:企業の戦略的SWOT分析
    McKinsey & Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ReShape Lifesciences Inc (RSLS)-医療機器分野:企業M&A・提携分析
    Summary ReShape Lifesciences Inc(ReShape Lifesciences) formerly known as EnteroMedics Inc, is a medical equipment provider that offers therapeutic and neuroregulator systems. The company designs and develops medical devices for the treatment of obesity and other disorders. It develops VBLOC therapy …
  • Cairn Energy Plc (CNE):企業の財務・戦略的SWOT分析
    Cairn Energy Plc (CNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Avanti Energy Inc (AVN):企業の財務・戦略的SWOT分析
    Summary Avanti Energy Inc (Avanti Energy), formerly known as Overlord Capital Ltd is an oil and gas exploration and production company. The company acquires, explores, and develops gas reserves in Central Italy. It re-develops the existing oil and gas reserves. Avanti Energy owns the Colle Santo gas …
  • Premier Veterinary Group Plc (PVG):企業の財務・戦略的SWOT分析
    Summary Premier Veterinary Group Plc (Premier Veterinary Group) formerly ARK Therapeutics Group Plc, is a veterinary care service provider. The company offers services such as premier pet care plan and premier buying group. Its pet care plan is a preventative healthcare program for dogs, cats, and r …
  • Scb Life Assurance Public Company Limited:企業の戦略・SWOT・財務分析
    Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Individual Restaurant Company Limited:企業の戦略・SWOT・財務分析
    Individual Restaurant Company Limited - Strategy, SWOT and Corporate Finance Report Summary Individual Restaurant Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • The Capital Group Companies, Inc.:企業の戦略・SWOT・財務分析
    The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Capital Group Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • VistaGen Therapeutics Inc (VTGN):医療機器:M&Aディール及び事業提携情報
    Summary VistaGen Therapeutics Inc (VistaGen) is a clinical stage biopharmaceutical company that develops new generation medicines for depression and neuropsychiatric disorders. The company’s pipeline product, AV-101, currently under Phase 2 clinical development, is an oral N-methyl-D-aspartate recep …
  • Golden Valley Mines Ltd. (GZZ):企業の財務・戦略的SWOT分析
    Golden Valley Mines Ltd. (GZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • QEP Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    QEP Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary QEP Resources Inc (QEP) is an independent oil and natural gas exploration and production company. It has operating interests in Northern Region chiefly in North Dakota, Wyoming and Utah; and Southe …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆